Don’t Skip this Article -Rome IV Summary

When I visited MIT, one of the slogans I heard was “Getting an Education from MIT is like taking a drink from a Fire Hose.” While this is a ridiculous notion, it is also true that the amount of information to consume, not just at MIT, but in so many areas is tremendous in quantity.  As such, one has to figure out what to read and what to toss.  For GI physicians, a recent summary (DA Drossman. Gastroenterol 2016; 1262-80) is worth a read due to the ubiquitous nature of the problems discussed.

Here were some key points:

  • “The possibility that passions or emotions could lead to the development of medical disease was first proposed by the Greek physician Claudius Galen.”
  • “Rome IV is a compendium of knowledge accumulated since Rome III” –10 years ago.

Some of the Changes:

  • New diagnoses:  Narcotic bowel syndrome, opioid-induced constipation, cannabinoid hyperemesis syndrome
  • Removal of functional terminology when possible…functional abdominal pain syndrome has been changed to centrally mediated abdominal pain syndrome
  • Threshold changes for diagnostic criteria
  • Addition of reflux hypersensitivity diagnosis.
  • Revision of Sphincter of Oddi  dysfunction disorder…  “driven by evidence that debunks the value of sphincterotomy for type III SOD.”
  • Emphasis that functional disorders exist on a spectrum with linked pathogenesis, particularly with regard to irritable bowel syndrome (IBS) subtypes.
  • Removal of the term discomfort for IBS criteria and using pain as the key criterion.

Approach to Patients with Functional GI Disorders:

  • The author discusses ways to engage patient to create partner-like interaction.
  • “Determine the immediate reason for the patient’s visit (eg. What led you to see me at this time?)”  Potential reasons: exacerbating factors, concern for serious disease, stressors, emotional comorbidity, impairment in daily functioning or hidden agenda (eg. disability, narcotics, litigation)
  • “Determine what the patient understands of the illness…What do you think is causing your symptoms?”
  • Provide a thorough explanation of the disorder.  “For example: ‘I understand you believe you have an infection that has been missed; as we understand it, the infection is gone but your nerves have even affected by the infection to make you feel like it is still there, similar to phantom limb.”
  • “Identify and respond realistically to the patient’s expectations for improvement (e.g. How do you feel I can be helpful to you?)”
  • Explain ways that stress can be associated.  “I understand you do not see stress as causing your pain, but you have mentioned how severe and disabling your  pain is.  How much do you think that is causing you emotional distress?”
  • “Set consistent limits..narcotic medication is not indicated because it can be harmful.”
  • “Involve patient in treatment plan (e.g. Let me suggest some treatments for you to consider).”
  • With regard to use of TCAs, the author explains that antidepressants can be used “to turn down the pain, and pain benefit occurs in doses lower than that used for depression.”  “Tricyclic antidepressants or the serotonin-norepinephrine reuptake inhibitors help control pain via central analgesia as well as provide relief of associated depressive symptoms.  The selective serotonin reuptake inhibitors are less effective for pain but can help reduce anxiety and associated depression.”
  • Establish an ongoing relationship.  “Whatever the result of this treatment, I am prepared to consider other options, and I will continue to work with you through this.”

My take: This summary provides a succinct update on a 6-year effort of 117 investigators/clinicians from 23 countries.  After reading this article, you will probably want to glance at the other articles in the same issue.

Vik Muniz Collage

Vik Muniz Collage

A closer look at the front wheel

A closer look at the front wheel

538: Gut Science Week

While FiveThirtyEight garners a lot of attention for its political and sports forecasts, there are often health-related posts.  This week is devoted to Gut Science Week.

Here’s the link: Gut Science Week Introduction

Here’s an excerpt:

One of the major leaps forward in gut science began with an accidental shooting at a trading post on June 6, 1822. A fur trader named Alexis St. Martin took a bullet in the abdomen, leaving him with a hole ripped through his muscle, bone and internal organs…

His doctor, William Beaumont, could literally tie a bit of food on a string, shove it into St. Martin’s stomach through the hole, and pull it back out again. Using this one weird trick, Beaumont extracted samples of the man’s gastric juices. Over eight years and more than 200 awkwardly invasive experiments, St. Martin and Beaumont gave humanity its first real understanding of how digestion works.

Another post: Everybody is Constipated, Nobody is Constipated

Here’s an excerpt:

Doctors use diagnostic criteria for constipation, where patients have to experience two or more of six symptoms:

  1. Straining during at least 25 percent of defecations
  2. Lumpy or hard stools in at least 25 percent of defecations
  3. Sensation of incomplete evacuation in at least 25 percent of defecations
  4. Sense of obstruction in at least 25 percent of defecations
  5. Manual maneuvers needed to facilitate at least 25 percent of defecations
  6. Fewer than three defecations per week

And a video: What Your Poop Says About You — FiveThirtyEight

Gut Science Week --FiveThirtyEight

Gut Science Week –FiveThirtyEight

Colorectal Adenomas

A good review on colorectal adenomas: WB Strum. NEJM 2016; 374: 1065.

A couple of points from review:

  • There has been a wealth of new data in last 10 years.
  • In 2016, ~134,000 persons in U.S. will be found to have colorectal cancer & 49.000 will die from it.
  • Adenomas are present in 20-53% of the U.S. population older than 50 years of age.
  • Adults in the U.S. have a lifetime risk of ~5% of adenocarcinoma.
  • Two major pathways from adenomas to adenocarcinoma: chromosomal instability and micro satellite instability via predominantly ~25 genes.
  • Screening interval recommendations (Table 1): 10 years for no polyps or juvenile polyps in rectum/sigmoid.
  • Aspirin therapy may be beneficial but apply to persons who have no increased risk of bleeding and are willing to take low-dose aspirin (81 mg) daily.  The greatest benefit is expected in persons 50 to 59 years and a potential benefit in 60 to 69 years of age.
  • Diets that are low in fat, regular physical exercise, maintenance of an appropriate body-mass index, and avoidance of smoking are recommended to lower risk.

Related full text article: Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: USPSTF Recommendations Excerpt:

The USPSTF recommends initiating low-dose aspirin use for the primary prevention of CVD and CRC in adults aged 50 to 59 years who have a 10% or greater 10-year CVD risk, are not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years. (B recommendation)The decision to initiate low-dose aspirin use for the primary prevention of CVD and CRC in adults aged 60 to 69 years who have a 10% or greater 10-year CVD risk should be an individual one.”

Related blog posts:

Colonic adenoma

CCFA Conference Notes 2016 (part 4) –Pregnancy and IBD

Pregnancy and IBD –Dr. Doug Wolf

Dr. Wolf reviewed infertility, pregnancy issues, and PIANO registry. This topic has been covered elsewhere in this blog (IBD and Pregnancy | gutsandgrowth). Vedolizumab is a FDA category B; thus far, it is considered fairly safe. Thiopurines are category D but overall thought to be low risk.

This blog entry has abbreviated/summarized this terrific presentation. Though not intentional, some important material is likely to have been omitted; in addition, transcription errors are possible as well.

Screen Shot 2016-04-16 at 2.30.04 PM

Screen Shot 2016-04-16 at 2.28.45 PM

Screen Shot 2016-04-16 at 2.29.35 PM

 

“The Couric Effect”

A recent commentary (Am J Gastroenterol advance online publication 29 March 2016; doi: 10.1038/ajg.2016.118) by Katie Couric provides a summary of her personal journey as an advocate for preventing colon cancer.

A good read: An Unexpected Turn: My Life as a Cancer Advocate

Here’s an excerpt:

“April is the cruelest month,” T.S. Eliot wrote in “The Waste Land,” and in 1997 it certainly was for my family. That’s when my husband Jay and I discovered he had stage IV colon cancer that had spread to his liver…and the beginning of a 9-month nightmare…

the University of Michigan found that my televised colonoscopy and educational outreach contributed to a sustained 19% increase in the number of colonoscopies performed nationwide. They called it “The Couric Effect”

Screen Shot 2016-03-29 at 4.59.42 PM

Anti-TNF therapy and Pregnancy -More Data

G Broms et al (Clin Gastroenterol Hepatol 2016; 14: 234-41) provide more data on the ‘low risk of birth defects for infants whose mothers are treated with anti-tumor necrosis factor agents during pregnancy.”

From a Danish/Swedish cohort of 1,272,424 live births (2004-2012), the authors found the following (in comparison to healthy infants):

  • Birth defects were increased in chronic inflammatory bowel disease: 4.8% vs. 4.2%
  • 43 (6.3%) of the infants born to women with IBD who received anti-TNF therapy (683) had birth defects.  The OR for any defect was 1.32 (CI 0.93-1.82).  The types of defects were generally similar, including VSD, ASD, hypospadias, and hydronephrosis

Limitations:

  • In infants of mothers with chronic diseases, it is possible that more careful screening identified some less apparent defects.
  • Study did not examine rates of stillborn or abortions

My take: Overall there is a slightly but not significantly increased risk in birth defects based on the use of anti-TNF therapy.  Stopping anti-TNF therapy is likely to be more detrimental.

Briefly noted: P Wils et al. Clin Gastroenterol Hepatol 2016; 14: 242-50.  This retrospective study of 122 patients showed that 65% had a clinical benefit within 3 months of receiving ustekinumab for Crohn’s disease refractory to anti-TNF therapy.  Concomitant immunosuppressant therapy was associated with an increased likelihood of benefit (OR 5.43)

Related blog posts:

IBD and Pregnancy

While managing inflammatory bowel disease during pregnancy is not within the scope of my practice as a pediatric gastroenterologist, it is helpful to have some familiarity with the issues.

Here’s a full-text link to AGA Guidelines: The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy

From the abstract, an excerpt:

Consensus was reached on 29 of the 30 recommendations considered. Preconception counseling and access to specialist care are paramount in optimizing disease management. In general, women on 5-ASA, thiopurine, or anti–tumor necrosis factor (TNF) monotherapy for maintenance should continue therapy throughout pregnancy. Discontinuation of anti-TNF therapy or switching from combination therapy to monotherapy may be considered in very select low-risk patients. Women who have a mild to moderate disease flare while on optimized 5-ASA or thiopurine therapy should be managed with systemic corticosteroid or anti-TNF therapy, and those with a corticosteroid-resistant flare should start anti-TNF therapy. Endoscopy or urgent surgery should not be delayed during pregnancy if indicated. Decisions regarding cesarean delivery should be based on obstetric considerations and not the diagnosis of IBD alone, with the exception of women with active perianal Crohn’s disease. With the exception of methotrexate, the use of medications for IBD should not influence the decision to breast-feed and vice versa. Live vaccinations are not recommended within the first 6 months of life in the offspring of women who were on anti-TNF therapy during pregnancy.

Gastro March2016

European Experience with Biosimilars

While there are numerous concerns regarding the use of biosimilar products, the preliminary experience with biosimilar infliximab has been favorable.

Full text link: European Experience of Infliximab Biosimilars for IBD (Gastroenterology & Hepatology)

Key points:

  • Biosimilars are leading to cost reductions of 30-40%.  In addition, to lowering the cost of infliximab, this is leading to reductions in costs for adalimumab and vedolizumab which are competing as 1st line therapies.
  • In the authors study of the first 210 patients, they did not find any difference in terms of immunogenicity or side effects.  In addition, efficacy was comparable to the ‘originator’ drug.

My take: Infliximab and adalimumab have been blockbuster medications for pharmaceutical companies, in part because they provide a great clinical benefit.  However, if biosimilars are truly biosimilar, the cost reductions will result in their widespread adoption.

Related blog post: Biosimilars -Position Statement  GutsandGrowth  This position statement: “Treatment of a child with sustained remission on a specific medication should not be switched to a biosimilar until clinical trials in IBD are available to support the safety and efficacy of such a change”

Castillo San Felipe del Morro

Castillo San Felipe del Morro

Microbiome Predicts Constipation plus two

In brief:

G Parthasarathy et al. Gastroenterol 2016; 150: 367-79.  Mucosal and fecal microbiota samples were collected from 25 healthy women and 25 women with chronic constipation.  Key finding: The mucosal, but not fecal, microbiota profile were 94% predictive of constipation. The associated editorial (pg 300) provides a framework for understanding these findings and show the complexity of trying understand the interations between diet, motility and microbes.

S Fukudo et al. Gastroenterol 2016; 150: 358-66.  This prospective study of Ramosetron for 576 women with IBS-D.  Key finding: 50.7% of treatment patients reported global improvement compared with 32.0% of control patients.  Patients had less abdominal pain, less discomfort, and better stool consistency.  Ramosetron, a 5-HT3 antagonist, has not been reported to cause ischemic colitis (in contrast to alosetron).

In followup to a post earlier in the week, another worrisome study on the Zika virus in pregnancy from NEJM. Here’s an excerpt:

Fetal abnormalities were detected by Doppler ultrasonography in 12 of the 42 ZIKV-positive women (29%) and in none of the 16 ZIKV-negative women. Adverse findings included fetal deaths at 36 and 38 weeks of gestation (2 fetuses), in utero growth restriction with or without microcephaly (5 fetuses), ventricular calcifications or other central nervous system (CNS) lesions (7 fetuses), and abnormal amniotic fluid volume or cerebral or umbilical artery flow (7 fetuses).

Farjado, Puerto Rico

Farjado, Puerto Rico

Guidelines: Microscopic Colitis & Vascular Diseases of the Liver

In brief:

AGA Microscopic Colitis Guideline: GC Nguyen et al. Gastroenterol 2016; 150: 242-6. Technical review DS Pardi et al. Gastroenterol 2016; 150: 247-74. Patient guide: pg 275.

EASL Clinical Practice Guidelines: Vascular diseases of the liver. J Hepatology 2016; 64: 179-202.  Topics covered include Budd-Chiari, Portal vein obstruction, Heriditary hemorrhagic telangiectasia, veno-occlusive disease of the liver, management of anticoagulation in liver disease